Effect of imeglimin on metabolic dysfunction-associated steatotic liver disease in individuals with type 2 diabetes
This exploratory study suggests that imeglimin may have beneficial effects in individuals with type 2 diabetes and elevated ALT (≥25 IU/L), potentially associated with MASLD. Randomized controlled trials are needed to confirm these findings.
Authors
- Nao Hasuzawa (ORCID: https://orcid.org/0000-0003-1344-8667)
- Masatoshi Nomura
- Mutsuyuki Demiya
- Yukihiro Inoguchi (ORCID: https://orcid.org/0000-0001-8135-0034)
- Ayako Nagayama
- Kenji Ashida (ORCID: https://orcid.org/0000-0001-8753-6016)
- Mizuki Gobaru
- Junjiro Rikitake
- Hitomi Nakayama (ORCID: https://orcid.org/0000-0002-2200-9810)
- Shimpei Iwata
- Naruyoshi Gyoutoku
Institutions
- Kurume University (JP)
- Yamamoto Hospital (JP)
- Nissan Tamagawa Hospital (JP)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-10-31
- DOI
- https://doi.org/10.1371/journal.pone.0335888
- Citations
- 1
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.35